Keywords: European Commission, DocMorris, K-Mail, Pfizer, Xalatan, Meda, Breakyl, Pediatric, Glaucoma, Pain
Commission clears JV by DocMorris and K-Mail Order; OK’s Pfizer’s pediatric Xalatan and Meda’s Breakyl
Article | 22 October 2010
The European Commission has granted clearance under the EU Merger Regulation to the creation of a joint venture between DocMorris ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
